• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于药代动力学/药效学模型,通过计算机模拟探索临床研究设计。

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.

作者信息

Gieschke R, Reigner B G, Steimer J L

机构信息

Pharma Development, F. Hoffmann-La Roche, Basel, Switzerland.

出版信息

Int J Clin Pharmacol Ther. 1997 Oct;35(10):469-74.

PMID:9352398
Abstract

Computer simulations have been successfully applied in various industries (e.g. automobile, aerospace) to make product development more efficient. Just recently, it was suggested to use simulations in support of clinical drug development for predicting clinical outcomes of planned trials. The methodological basis for this approach is provided by pharmacokinetic and pharmacodynamic mathematical models together with Monte Carlo techniques. In the present paper, the basic notions of clinical trial simulation are introduced and illustrated with the example of an oral anticancer drug. It is shown that computer simulation helps to evaluate consequences of design features on safety and efficacy assessment of the drug which are not easily obtained otherwise. An overview of existing simulation resources with respect to training and software is provided.

摘要

计算机模拟已成功应用于各个行业(如汽车、航空航天),以提高产品开发效率。最近,有人建议使用模拟来支持临床药物开发,以预测计划试验的临床结果。这种方法的方法论基础是由药代动力学和药效学数学模型以及蒙特卡洛技术提供的。在本文中,介绍了临床试验模拟的基本概念,并以一种口服抗癌药物为例进行了说明。结果表明,计算机模拟有助于评估设计特征对药物安全性和有效性评估的影响,而这些影响用其他方法不易获得。本文还提供了有关培训和软件的现有模拟资源概述。

相似文献

1
Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.基于药代动力学/药效学模型,通过计算机模拟探索临床研究设计。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):469-74.
2
Study design and simulation approach.研究设计与模拟方法。
Handb Exp Pharmacol. 2011;205:125-48. doi: 10.1007/978-3-642-20195-0_6.
3
Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.药物计量学:用于改善临床药物开发决策的建模与模拟工具。
Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58. doi: 10.1007/BF03190058.
4
PK/PD modelling and simulations: utility in drug development.药代动力学/药效学建模与模拟:在药物研发中的应用
Drug Discov Today. 2008 Apr;13(7-8):341-6. doi: 10.1016/j.drudis.2008.01.003. Epub 2008 Mar 7.
5
A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.一种使用GastroPlus作为药代动力学模拟工具的临床前制剂开发策略以及应用于犬类研究的统计筛选设计。
Eur J Pharm Sci. 2006 Jan;27(1):91-9. doi: 10.1016/j.ejps.2005.08.011. Epub 2005 Oct 10.
6
Weibull prediction of event times in clinical trials.临床试验中事件时间的威布尔预测。
Pharm Stat. 2008 Apr-Jun;7(2):107-20. doi: 10.1002/pst.271.
7
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.癌症药物研发中的0期临床试验:从美国食品药品监督管理局指南到临床实践
Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9.
8
[Computer simulations to support drug therapy in children].[支持儿童药物治疗的计算机模拟]
Med Monatsschr Pharm. 2008 Nov;31(11):429-33.
9
Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.通过群体药代动力学和药效学模型模拟预测抗精神分裂症药物(富马酸喹硫平)3期临床试验的结果。
Clin Pharmacol Ther. 2000 Nov;68(5):568-77. doi: 10.1067/mcp.2000.110975.
10
[Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].[使用CTS和PK-PD模型预测总体参数不确定性对临床试验效能的影响]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009 Feb;26(1):42-6, 62.

引用本文的文献

1
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.模型引导的药物发现与开发中的良好实践:实践、应用与文档记录
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.
2
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.模拟评估卡培他滨联合多西紫杉醇不同剂量治疗转移性乳腺癌的 II 期非劣效性试验。
CPT Pharmacometrics Syst Pharmacol. 2012 Dec 26;1(12):e19. doi: 10.1038/psp.2012.20.
3
Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.
在大鼠中评估普瑞巴林-西地那非相互作用的群体药代动力学模型:模拟在临床前 PK-PD 研究设计中的应用。
Pharm Res. 2009 Oct;26(10):2259-69. doi: 10.1007/s11095-009-9942-y. Epub 2009 Aug 11.
4
Facilitation of drug evaluation in children by population methods and modelling.运用群体方法和模型促进儿童药物评估。
Clin Pharmacokinet. 2008;47(4):231-43. doi: 10.2165/00003088-200847040-00002.
5
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?抗癌药物研发与应用中的建模与模拟:一种未得到充分利用的工具?
J Pharmacokinet Pharmacodyn. 2004 Dec;31(6):419-40. doi: 10.1007/s10928-005-5910-2.
6
A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.一种用于描述生物标志物对伊班膦酸钠(一种用于治疗骨质疏松症的新型双膦酸盐)反应的半机制和机制性群体药代动力学-药效学模型。
Br J Clin Pharmacol. 2004 Dec;58(6):618-31. doi: 10.1111/j.1365-2125.2004.02224.x.
7
Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.临床药理学:药物研发与药物警戒中的特殊安全性考量
Drug Saf. 2004;27(8):535-54. doi: 10.2165/00002018-200427080-00006.
8
Pharmacokinetic-pharmacodynamic guided trial design in oncology.肿瘤学中基于药代动力学-药效学的试验设计
Invest New Drugs. 2003 May;21(2):225-41. doi: 10.1023/a:1023577514605.
9
Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.新药研发中的临床药代动力学/药效学及基于生理学的药代动力学建模:卡培他滨的经验
Invest New Drugs. 2003 May;21(2):195-223. doi: 10.1023/a:1023525513696.
10
Accounting for noncompliance in pharmacoeconomic evaluations.药物经济学评价中对不依从性的考量
Pharmacoeconomics. 2001;19(12):1185-97. doi: 10.2165/00019053-200119120-00001.